**Name of Journal:** *World Journal of Gastrointestinal Pharmacology and Therapeutics*

**Manuscript NO:** 64712

**Manuscript Type:** EVIDENCE REVIEW

**Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease**

Rocha R *et al*. Nutritional status and postoperative in IBD

Raquel Rocha, Geisa de J Santos, Genoile Oliveira Santana

**Raquel Rocha**, **Geisa de J Santos,** Department of Sciences of Nutrition, School of Nutrition, Federal University of Bahia, Salvador 40110-150, Bahia, Brazil

**Genoile Oliveira Santana,** Department of Life Sciences, State University of Bahia, Salvador 40110060, Bahia, Brazil

**Author contributions:** de J Santos G and Rocha R wrote the article; Rocha R and Santana GO reviewed the article.

**Supported by** FAPESB (Fundação de Amparo à Pesquisa do Estado da Bahia).

**Corresponding author: Raquel Rocha, PhD, Professor,** Department of Sciences of Nutrition, School of Nutrition, Federal University of Bahia, Avenida Araújo Pinho 32, Salvador 40110-150, Bahia, Brazil. [raquelrocha2@yahoo.com.br](mailto:raquelrocha2@yahoo.com.br)

**Received:** February 22, 2021

**Revised:** May 21, 2021

**Accepted:** August 30, 2021

**Published online:**

**Abstract**

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory diseases that affect the gastrointestinal tract, including Crohn's disease (CD) and ulcerative colitis. Surgery is a treatment option, and more than half of the patients with CD will undergo surgical interventions over the course of the disease. Postoperative complications are common in IBD patients, the most frequent being intra-abdominal sepsis, infection of the surgical site, and adynamic ileum, and nutritional status is a factor that can influence postoperative outcome. Recent studies have shown that malnutrition, obesity, sarcopenia, and myosteatosis are predictors of surgical complications. However, most were retrospective studies with small patient samples and heterogeneity of clinical and nutritional assessment methods, which limit the extrapolation of data. Therefore, knowing the pathophysiological mechanisms of IBD and identifying the best parameters for assessing nutritional status are essential for prompt implementation of adequate nutritional interventions.

**Key Words:** Inflammatory bowel diseases; Crohn disease; Ulcerative colitis; Nutritional status; Postoperative complications; Surgery

Rocha R, de J Santos G, Santana GO. Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease. *World J Gastrointest Pharmacol Ther* 2021; In press

**Core Tip:** Nutritional status influences the postsurgical results of patients with inflammatory bowel diseases (IBDs). Despite the limitations of previously published studies, malnutrition, obesity, sarcopenia, and myosteatosis were identified as negative predictive factors for postoperative complications in people diagnosed with IBDs.

**INTRODUCTION**

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory diseases that affect the gastrointestinal tract, and the most common are Crohn's disease (CD) and ulcerative colitis (UC)[1]. Although the incidence of IBD in most Western countries is stable, the prevalence exceeds 0.3% in some regions, which results in a high disease burden[2]. In addition to drug therapy, surgical interventions are needed by most patients with CD[3]. In IBD, surgery is indicated for clinical intractability, complications, and neoplasms, and is considered an option in CD patients with isolated ileal disease[4]. Postoperative complications are frequent in IBD, especially intra-abdominal sepsis, surgical site infection (SSI), and adynamic ileum[5-9]. Increased understanding of the effects of nutritional status on surgical outcomes and the patient characteristics that are predictive of surgery-associated complications are essential for prompt implementation of adequate nutritional interventions[10]. The purpose of this review was to gather scientific evidence on the influence of nutritional status in the postoperative period of people with IBD.

**IBDs**

Although the details are not completely clear, it is assumed that the pathogenesis of IBD involves genetic, environmental, and immunological factors[1]. The clinical course of the disease is highly variable but is most often characterized by periods of activity and remission[11]. The last 100 years have seen an increase and stabilization in the occurrence of IBD in Western countries, while in some countries in Africa, Asia, and South America, the incidence continues to increase and still lacks stability. This trend has been attributed mainly to Westernization and recent industrialization in those regions. Given the reality and economic impact of IBD, healthcare systems and professionals must be prepared to implement prevention policies, conduct scientific research, and provide adequate attention to the IBD population[12,13]. Currently, the therapeutic objectives of IBD include symptomatic treatment, induction of clinical remission, and other goals, such as the prevention of complications, healing of the mucosa, improvement of quality of life, and remission without the need of steroids[14,15]. In addition to medications (*e.g.*, aminosalicylates, corticosteroids, immunomodulators, and immunobiologicals) and enteral nutritional therapy exclusively for the pediatric population, surgical procedures can also be used to treat IBD patients[16,17].

**SURGICAL TREATMENT**

Elective surgery may be indicated for UC and CD patients[18]. IBD patients presenting with toxic colitis, bleeding, perforations, obstructions, and abscesses usually require emergency surgical interventions[19]. Chronic intestinal inflammation and prolonged treatment with immunosuppressive drugs increase the risk of the development of gastrointestinal neoplasms in IBD patients[20]. The presence of IBD in patients with colorectal cancer increases the risk of prolonged hospitalization following surgery, hospital readmission within 30 d of discharge, open surgery, total colectomy, total proctocolectomy, deep vein thrombosis, and postoperative infection[21].

Most people diagnosed with CD will need surgery, and approximately half will have a recurrence after intestinal resection. The presence of disease in any region of the small intestine, perianal fistula, and an age between 45 and 59 years increase the relative risk of surgery[3]. The main objectives of surgical treatment are symptom control, maintenance of intestinal function, and anatomical preservation of organs[18]. Studies have shown that the percentage of postoperative complications varies from 9% to 33%, with intra-abdominal sepsis following an anastomotic leak, intra-abdominal collection, or a parietal abscess; SSI, and adynamic ileum (*i.e.* the absence of bowel muscle contraction movements)[22,23].

Patients with CD undergoing ileal resection often experience malabsorption of bile acids. Bile acids are essential for the digestion of fats, and their active reabsorption occurs in the distal ileum. The absence of this portion of the intestine compromises the digestion of lipids in the diet, promoting steatorrhea, fecal excretion of fats. In addition, ileal resection and the consequent accumulation of bile acids in the lumen can increase intestinal permeability and motility, impair the integrity of the mucosa, promote bacterial overgrowth, and favor the formation of kidney and gallstones. The selenium homotaurocholic acid test is the gold standard method for detecting the condition, and the first line of treatment is the use of intraluminal bile acid ligands such as cholestyramine[24-27]. Surgery is performed less often in patients with UC and may be indicated in cases of neoplasia, dysplasia, and refractory disease. The most common interventions include total proctocolectomy with permanent terminal ileostomy and the making of an ileal pouch with anastomosis to the anal canal. Among the main risk factors for both early colectomy and late colectomy are male sex and hospitalization at diagnosis[18,28]. The occurrence of postoperative complications in UC varied from 9% to 65% (early) and from 17% to 55% (late), and was higher than the occurrence of complications in CD. Adynamic ileum, infection, and pouchitis were the most common complications observed in the UC population[29,30]. Compared with open surgery, laparoscopy is a minimally invasive technique with better 30 d postoperative outcomes, especially in relation to the need for a pulmonary ventilator after 48 h, organ space infection, superficial and deep SSI, urinary tract infection, and renal failure[31]. It should be noted that regardless of the type of surgery, the surgeon's primary goal is to ensure performance of a long-lasting, reproducible, and safe procedure[32].

Although the literature is controversial, a systematic review and meta-analysis found that the use of corticosteroids and anti-tumor necrosis factor increased the risk of intra-abdominal infections in the postoperative period[33]. In addition, in the era of biological products, it has been observed that after non-elective surgery, mortality has remained high in UC and has slightly decreased in CD. A population-based study found that mortality was primarily associated with comorbidities and age[34,35].

**NUTRITIONAL STATUS AND POSTOPERATIVE COMPLICATIONS**

Surgery is an invasive procedure that results in tissue damage, the breaking of a physical barrier, and possible exposure to microorganisms that result in inflammation and metabolic stress. Inflammation involves innate and adaptive immune responses and pro- and anti-inflammatory mediators. The severity of the inflammatory response depends, among other factors, on age and the type and location of the surgery, the medications used, and preoperative health status[36].

***Malnutrition***

In patients with IBD, malnutrition often prolongs the inflammatory response and slows recovery from illness and surgery, hinders wound healing, and is related to increased hospital stay and healthcare costs[37-39]. Various factors contribute to the deterioration of nutritional status in this population, such as reduced food intake, increased intestinal losses, malabsorption of nutrients, increased nutritional needs associated with systemic inflammation, and iatrogenic factors (*e.g.*, surgery and medications)[40,41]. As malnutrition is a modifiable risk factor for adverse outcomes of surgery, prompt identification enables early nutritional interventions[10], several studies have investigated methods of preoperative nutritional assessment[42-45].

Body mass index (BMI) is a practical, widely used predictor of surgical complications. A low BMI seems to increase the risk of postoperative infectious complications and intra-abdominal sepsis in patients with CD, and is better predictor than serum albumin concentration[46,47]. However, recent studies have identified preoperative hypoalbuminemia is a risk factor for complications in both CD and UC, and that the incidence of undesirable outcomes was increased in eutrophic patients with hypoalbuminemia[45,48]. It is noteworthy that the studies were retrospective and had small patient samples, therefore, the results should be interpreted with caution[46,47]. In fact, serum albumin may not be a good marker of the nutritional status of patients with IBD, especially in the active phase[49].

Both albumin and C-reactive protein (CRP) are acute-phase proteins, and their concentrations change with the inflammation that occurs after surgical trauma[50]. The CRP/albumin ratio (CAR) is considered as a novel prognostic index based on inflammation. A study including IBD patients undergoing elective colorectal surgery found that postoperative CAR predicted surgical complications, more accurately than CRP alone. Patients with a CAR ≥ 2.2 had increased risks of complications, prolonged hospital stays, and SSIs, which indicated that value was of possible use as a cutoff for the early detection of undesirable results[51]. The CAR was also able to predict postsurgical survival in people with colorectal cancer[52].

Considering the limitations of nutritional status markers, the preoperative assessment must be complete, including the assessment of nutritional risk scores and information about food consumption and weight loss[53]. The guidelines of the European Society for Clinical Nutrition and Metabolism on nutrition in surgery define severe nutritional risk as the presence of least one of the following: Weight loss > 10%-15% in 6 mo; a BMI < 18.5 kg/m²; Subjective Global Assessment grade C or Nutritional Risk Screening > 5; or a preoperative serum albumin < 30 g/L without evidence of hepatic or renal dysfunction[38].

***Obesity***

The prevalence of overweight and obesity has increased in both the general population and in people with IBD[54-56]. Obesity is an inflammatory state, and the metabolic activity of adipose tissue includes the secretion of pro- and anti-inflammatory cytokines that can promote immune-mediated diseases such as IBD[57]. Data on the influence of obesity on IBD are controversial. Some studies show an association with unfavorable outcomes of the disease, such as the need for surgery and hospitalization, reduced drug efficacy, and complications[57-59]. Others have not demonstrated such associations[60-63] and consider obesity to be a marker of less severe disease[62].

It has been suggested that obesity has a negative influence on postoperative results[57]. Despite having less disease severity at the time of surgery, obesity increased the risk of SSI in CD patients after ileocolic resection, as well as the risk of requiring laparoscopic modification of conventional surgery, which may lead to worse outcomes in the future[31,64]. A recent meta-analysis concluded that obesity was associated with general postsurgical complications, high SSI rates, greater blood loss, and longer hospital stays in patients with IBD[65]. A point to be highlighted is that SSI is related to the size of the surgical extraction site, which tends to be larger in obese patients[64]. Because SSI is likely to prolong hospitalization and has been shown to increase readmission rates after colectomy, preoperative weight loss has been suggested in order to minimize it[66,67].

Few studies have investigated the effect of weight loss on the outcomes following surgery for IBD[57]. Bariatric surgery is one of the ways of treating obesity[68], but its use in IBD is limited because of the complexity of those diseases and the scarcity of studies to support the decision-making of health professionals[69]. Reviews of the impact of bariatric surgery on the clinical course of IBD found that it is relatively safe and reduces the risk of complications[69,70]; however, more robust original articles evaluating surgical outcomes must be added to the literature to increase the reliability of those findings. It should be noted that malnutrition is common in patients with IBD and that people with high BMIs may also have nutritional deficiencies[37,71,72]. Therefore, it is essential to carry out a thorough nutritional assessment of possible candidates for bariatric surgery[69].

Most studies use BMI to determine obesity. However, the index has limitations, such as the inability to distinguish body composition and fat distribution. Although interest in the role of visceral fat in IBD patients has increased recently, few clinical trials have been conducted. The available results include associations between body fat measurements (mesenteric fat index, morphometric analysis, visceral fat area) and inflammation and postsurgical complications that were not observed when BMI was chosen as a variable[73-75].

***Sarcopenia***

In IBD patients, malnutrition and excess weight can coexist with sarcopenia, which is a skeletal muscle syndrome characterized by progressive and generalized reduction in the quantity and quality (*i.e.* strength or physical performance) of muscle mass[76]. The etiology of sarcopenia is multifactorial, involving aging, physical inactivity, presence of other diseases (*e.g.*, inflammatory, malignant and endocrine), organ failure, and inadequate intake or use of nutrients (*e.g.*, anorexia, malabsorption, limited access to healthy foods and drug interactions). In the last 10 years, several studies conducted in different populations reported that muscle strength has a prominent role[77,78].

In a meta-analysis, sarcopenia was found to be an independent risk factor for the need of surgery and the occurrence of postoperative complications, with no difference between UC and CD. However, the data should not be extrapolated, as all the studies evaluated sarcopenia only by body composition and the muscle mass; type of surgery and postsurgical outcome data were heterogeneous[79]. In a study that evaluated only people with CD, Galata *et al*[80] observed that the skeletal muscle mass index was the only risk factor for abscesses and anastomotic leaks. Patients with sarcopenia had lower serum albumin levels and BMIs and higher CRP levels, which can be useful indicators for nutritional screening of the syndrome[79].

Although it is more common in malnourished people, sarcopenia can affect those who are overweight. A study carried out in 90 IBD patients with sarcopenia defined as a low skeletal muscle mass in a computed tomography cross-section at the L3 vertebral level, found that a BMI ≥ 25 kg/m² predicted the need for surgery. However, the sample number was limited (*n* = 3) and there was no information on the surgical results[81].

***Myosteatosis***

Myosteatosis is a negative prognostic factor in cancer and has been associated with worse overall survival in a variety of cancers[82,83]. The pathophysiology of myosteatosis is not well understood, but it is believed that there is a relationship between aging and excess weight that results in ectopic fat deposition in skeletal muscle[84]. O’Brien *et al*[85] found that the hospital stays were longer and readmissions 30 d after bowel resection were more frequent in IBD patients with myosteatosis. There are few recent studies of the effects of the change in body composition that occurs in myosteatosis. Better knowledge of the pathogenesis and validation of diagnostic criteria for myosteatosis are essential for conducting reliable studies to elucidate the impact of this condition on postoperative evolution and to accurately assess preoperative nutritional status[83].

***Nutritional support***

Insufficient food intake increases the risk of postoperative complications of abdominal surgery. The optimization of nutritional status in the preoperative period contributes to better surgical results in CD patients[86,87]. Given the importance of perioperative nutritional support, new IBD guidelines recommend early initiation of nutritional therapy in patients with malnutrition and/or unsatisfactory food consumption. The recommendation stems from a prediction of the inability to eat for more than 7 d in the perioperative period and impossibility of maintaining an oral intake above 60%-75% of nutritional needs for more than 10 d[27].

The choice of the type of nutritional therapy will depend on the clinical condition and nutritional status of the patient. Whenever possible, one should choose enteral nutrition (EN) over parenteral nutrition (PN). However, if EN does not supply more than 60% of the energy needs, then EN should be supplemented by PN, especially in the perioperative period. Exclusive PN is indicated in patients with diarrhea and severe vomiting, absence of access, bowel obstruction, severe shock, intestinal ischemia, high output fistula, and severe intestinal bleeding[27,53].

Most of the guidelines contained in the Enhanced Recovery After Surgery protocols can be applied to IBD patients undergoing surgical interventions. From a metabolic and nutritional perspective, some precautions must be taken in order to speed up postoperative recovery and reduce hospital stay. They include avoiding long periods of fasting before surgery, promoting metabolic and blood glucose control, reducing factors that intensify catabolism or impair the function of the gastrointestinal tract, re-establishing oral feeding as soon as possible, and promoting early mobilization in order to favor protein synthesis[27,38,53].

**CONCLUSION**

Surgical intervention during the course of IBD is a common practice, and postsurgical complications such as intra-abdominal sepsis, SSI, and adynamic ileum are prevalent. Nutritional status that involves malnutrition, obesity, sarcopenia, and myosteatosis is predictive of the worst outcomes of surgery by increasing the risk infectious and noninfectious complications. Further studies are needed to understand the pathophysiological mechanisms, standardize diagnostic criteria and determine the best preoperative nutritional assessments. This knowledge is essential to establish measures to prevent postsurgical complication in IBD patients.

**REFERENCES**

1 **Bernstein CN**, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, Ouyang Q, Rey JF, Sood A, Steinwurz F, Watermeyer G, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. *J Clin Gastroenterol* 2016; **50**: 803-818 [PMID: 27741097 DOI: 10.1097/MCG.0000000000000660]

2 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2017; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

3 **Bernell O**, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. *Ann Surg* 2000; **231**: 38-45 [PMID: 10636100 DOI: 10.1097/00000658-200001000-00006]

4 **Ponsioen CY**, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Laparoscopic ileocaecal resection *vs* infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. *Lancet Gastroenterol Hepatol* 2017; **2**: 785-792 [PMID: 28838644 DOI: 10.1016/S2468-1253(17)30248-0]

5 **Peyrin-Biroulet L**, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Aliment Pharmacol Ther* 2016; **44**: 807-816 [PMID: 27534519 DOI: 10.1111/apt.13763]

6 **Kim JY**, Zaghiyan K, Lightner A, Fleshner P. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study. *BMC Surg* 2020; **20**: 46 [PMID: 32138717 DOI: 10.1186/s12893-020-00698-8]

7 **Fumery M**, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B, Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C, Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M; REMIND study group investigators. Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. *Am J Gastroenterol* 2017; **112**: 337-345 [PMID: 27958285 DOI: 10.1038/ajg.2016.541]

8 **Yu CS**, Jung SW, Lee JL, Lim SB, Park IJ, Yoon YS, Kim CW, Yang SK, Ye BD, Park SH, Han M, Kim JC. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease. *Inflamm Bowel Dis* 2019; **25**: 1559-1568 [PMID: 30753560 DOI: 10.1093/ibd/izz010]

9 **Kline BP**, Weaver T, Brinton DL Jr, Deiling S, Yochum GS, Berg AS, Koltun WA. Clinical and Genetic Factors Associated With Complications After Crohn's Ileocolectomy. *Dis Colon Rectum* 2020; **63**: 357-364 [PMID: 32045400 DOI: 10.1097/DCR.0000000000001574]

10 **Williams DGA**, Molinger J, Wischmeyer PE. The malnourished surgery patient: a silent epidemic in perioperative outcomes? *Curr Opin Anaesthesiol* 2019; **32**: 405-411 [PMID: 30893119 DOI: 10.1097/ACO.0000000000000722]

11 **Romberg-Camps MJ**, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. *Am J Gastroenterol* 2009; **104**: 371-383 [PMID: 19174787 DOI: 10.1038/ajg.2008.38]

12 **Kaplan GG**. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 720-727 [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150]

13 **Kaplan GG**, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* 2017; **152**: 313-321.e2 [PMID: 27793607 DOI: 10.1053/j.gastro.2016.10.020]

14 **Peyrin-Biroulet L**, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, Danese S, Sturm A; Scientific Committee of the European Crohn's and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. *J Crohns Colitis* 2011; **5**: 477-483 [PMID: 21939925 DOI: 10.1016/j.crohns.2011.06.009]

15 **Ooi CJ**, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. *J Gastroenterol Hepatol* 2016; **31**: 56-68 [PMID: 25819311 DOI: 10.1111/jgh.12958]

16 **Dziechciarz P**, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. *Aliment Pharmacol Ther* 2007; **26**: 795-806 [PMID: 17767463 DOI: 10.1111/j.1365-2036.2007.03431.x]

17 **Lamb CA**, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019; **68**: s1-s106 [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484]

18 **Feinberg AE**, Valente MA. Elective Abdominal Surgery for Inflammatory Bowel Disease. *Surg Clin North Am* 2019; **99**: 1123-1140 [PMID: 31676052 DOI: 10.1016/j.suc.2019.08.004]

19 **Goldstone RN**, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease. *Surg Clin North Am* 2019; **99**: 1141-1150 [PMID: 31676053 DOI: 10.1016/j.suc.2019.08.007]

20 **Axelrad JE**, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. *World J Gastroenterol* 2016; **22**: 4794-4801 [PMID: 27239106 DOI: 10.3748/wjg.v22.i20.4794]

21 **Ramsey M**, Krishna SG, Stanich PP, Husain S, Levine EJ, Conwell D, Hinton A, Zhang C. Inflammatory Bowel Disease Adversely Impacts Colorectal Cancer Surgery Short-term Outcomes and Health-Care Resource Utilization. *Clin Transl Gastroenterol* 2017; **8**: e127 [PMID: 29189768 DOI: 10.1038/ctg.2017.54]

22 **Alves A**, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. *Dis Colon Rectum* 2007; **50**: 331-336 [PMID: 17252288 DOI: 10.1007/s10350-006-0782-0]

23 **Tang S**, Dong X, Liu W, Qi W, Ye L, Yang X, Cao Q, Ge X, Zhou W. Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study. *Int J Colorectal Dis* 2020; **35**: 727-737 [PMID: 32060607 DOI: 10.1007/s00384-019-03481-1]

24 **Lenicek M**, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, Vitek L. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. *Inflamm Bowel Dis* 2011; **17**: 1322-1327 [PMID: 21058331 DOI: 10.1002/ibd.21502]

25 **Camilleri M**. Advances in understanding of bile acid diarrhea. *Expert Rev Gastroenterol Hepatol* 2014; **8**: 49-61 [PMID: 24410472 DOI: 10.1586/17474124.2014.851599]

26 **Vítek L**. Bile acid malabsorption in inflammatory bowel disease. *Inflamm Bowel Dis* 2015; **21**: 476-483 [PMID: 25248001 DOI: 10.1097/MIB.0000000000000193]

27 **Bischoff SC**, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Forbes A. ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. *Clin Nutr* 2020; **39**: 632-653 [PMID: 32029281 DOI: 10.1016/j.clnu.2019.11.002]

28 **Targownik LE**, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. *Am J Gastroenterol* 2012; **107**: 1228-1235 [PMID: 22613902 DOI: 10.1038/ajg.2012.127]

29 **Feuerstein JD**, Curran T, Alosilla M, Cataldo T, Falchuk KR, Poylin V. Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common. *Dig Dis Sci* 2018; **63**: 713-722 [PMID: 29353444 DOI: 10.1007/s10620-018-4922-x]

30 **Schineis C**, Lehmann KS, Lauscher JC, Beyer K, Hartmann L, Margonis GA, Michel J, Degro CE, Loch FN, Speichinger F, Kreis ME, Kamphues C. Colectomy with ileostomy for severe ulcerative colitis-postoperative complications and risk factors. *Int J Colorectal Dis* 2020; **35**: 387-394 [PMID: 31865435 DOI: 10.1007/s00384-019-03494-w]

31 **Gaglani T**, Davis CH, Bailey HR, Cusick MV. Trends and Outcomes for Minimally Invasive Surgery for Inflammatory Bowel Disease. *J Surg Res* 2019; **235**: 303-307 [PMID: 30691810 DOI: 10.1016/j.jss.2018.09.075]

32 **Schwartzberg DM**, Remzi FH. The Role of Laparoscopic, Robotic, and Open Surgery in Uncomplicated and Complicated Inflammatory Bowel Disease. *Gastrointest Endosc Clin N Am* 2019; **29**: 563-576 [PMID: 31078253 DOI: 10.1016/j.giec.2019.02.012]

33 **Law CCY**, Koh D, Bao Y, Jairath V, Narula N. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. *Inflamm Bowel Dis* 2020; **26**: 1796-1807 [PMID: 32047894 DOI: 10.1093/ibd/izaa020]

34 **Justiniano CF**, Aquina CT, Becerra AZ, Xu Z, Boodry CI, Swanger AA, Monson JRT, Fleming FJ. Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics. *Ann Surg* 2019; **269**: 686-691 [PMID: 29232213 DOI: 10.1097/SLA.0000000000002628]

35 **Guasch M**, Vela E, Mañosa M, Clèries M, Cañete F, Parés D, Guarga À, Troya J, Calafat M, Domènech E. Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern Europe. *Dig Liver Dis* 2021; **53**: 54-60 [PMID: 33082087 DOI: 10.1016/j.dld.2020.09.026]

36 **Alazawi W**, Pirmadjid N, Lahiri R, Bhattacharya S. Inflammatory and Immune Responses to Surgery and Their Clinical Impact. *Ann Surg* 2016; **264**: 73-80 [PMID: 27275778 DOI: 10.1097/SLA.0000000000001691]

37 **Yamamoto T**, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease--epidemiology and treatment. *Aliment Pharmacol Ther* 2009; **30**: 99-112 [PMID: 19438426 DOI: 10.1111/j.1365-2036.2009.04035.x]

38 **Weimann A**, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, Laviano A, Ljungqvist O, Lobo DN, Martindale R, Waitzberg DL, Bischoff SC, Singer P. ESPEN guideline: Clinical nutrition in surgery. *Clin Nutr* 2017; **36**: 623-650 [PMID: 28385477 DOI: 10.1016/j.clnu.2017.02.013]

39 **O'Sullivan M**, O'Morain C. Nutrition in inflammatory bowel disease. *Best Pract Res Clin Gastroenterol* 2006; **20**: 561-573 [PMID: 16782529 DOI: 10.1016/j.bpg.2006.03.001]

40 **Hartman C**, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. *World J Gastroenterol* 2009; **15**: 2570-2578 [PMID: 19496185 DOI: 10.3748/wjg.15.2570]

41 **Balestrieri P**, Ribolsi M, Guarino MPL, Emerenziani S, Altomare A, Cicala M. Nutritional Aspects in Inflammatory Bowel Diseases. *Nutrients* 2020; **12** [PMID: 32023881 DOI: 10.3390/nu12020372]

42 **Zhou W**, Cao Q, Qi W, Xu Y, Liu W, Xiang J, Xia B. Prognostic Nutritional Index Predicts Short-Term Postoperative Outcomes After Bowel Resection for Crohn's Disease. *Nutr Clin Pract* 2017; **32**: 92-97 [PMID: 27566600 DOI: 10.1177/0884533616661844]

43 **Liu X**, Wu X, Zhou C, Hu T, Ke J, Chen Y, He X, Zheng X, He X, Hu J, Zhi M, Gao X, Hu P, Wu X, Lan P. Preoperative hypoalbuminemia is associated with an increased risk for intra-abdominal septic complications after primary anastomosis for Crohn's disease. *Gastroenterol Rep (Oxf)* 2017; **5**: 298-304 [PMID: 29230300 DOI: 10.1093/gastro/gox002]

44 **Okita Y**, Araki T, Okugawa Y, Kondo S, Fujikawa H, Hiro J, Inoue M, Toiyama Y, Ohi M, Uchida K, Kusunoki M. The prognostic nutritional index for postoperative infectious complication in patients with ulcerative colitis undergoing proctectomy with ileal pouch-anal anastomosis following subtotal colectomy. *J Anus Rectum Colon* 2019; **3**: 91-97 [PMID: 31559374 DOI: 10.23922/jarc.2018-032]

45 **Ge X**, Liu H, Tang S, Wu Y, Pan Y, Liu W, Qi W, Ye L, Cao Q, Zhou W. Preoperative hypoalbuminemia is an independent risk factor for postoperative complications in Crohn's disease patients with normal BMI: A cohort study. *Int J Surg* 2020; **79**: 294-299 [PMID: 32505647 DOI: 10.1016/j.ijsu.2020.05.064]

46 **Zhu Y**, Zhou W, Qi W, Liu W, Chen M, Zhu H, Xiang J, Xie Q, Chen P. Body mass index is a practical preoperative nutritional index for postoperative infectious complications after intestinal resection in patients with Crohn's disease. *Medicine (Baltimore)* 2017; **96**: e7113 [PMID: 28591060 DOI: 10.1097/MD.0000000000007113]

47 . Body Mass Index Is a Marker of Nutrition Preparation Sufficiency Before Surgery for Crohn's Disease From the Perspective of Intra-Abdominal Septic Complications: A Retrospective Cohort Study. *Medicine (Baltimore)* 2015; **94**: 1 [PMID: 26334908 DOI: 10.1097/MD.0000000000001455]

48 **Sofo L**, Caprino P, Schena CA, Sacchetti F, Potenza AE, Ciociola A. New perspectives in the prediction of postoperative complications for high-risk ulcerative colitis patients: machine learning preliminary approach. *Eur Rev Med Pharmacol Sci* 2020; **24**: 12781-12787 [PMID: 33378027 DOI: 10.26355/eurrev\_202012\_24178]

49 **Vagianos K**, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. *JPEN J Parenter Enteral Nutr* 2007; **31**: 311-319 [PMID: 17595441 DOI: 10.1177/0148607107031004311]

50 **Gabay C**, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 1999; **340**: 448-454 [PMID: 9971870 DOI: 10.1056/NEJM199902113400607]

51 **Ge X**, Cao Y, Wang H, Ding C, Tian H, Zhang X, Gong J, Zhu W, Li N. Diagnostic accuracy of the postoperative ratio of C-reactive protein to albumin for complications after colorectal surgery. *World J Surg Oncol* 2017; **15**: 15 [PMID: 28069031 DOI: 10.1186/s12957-016-1092-1]

52 **Ishizuka M**, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. *Ann Surg Oncol* 2016; **23**: 900-907 [PMID: 26530445 DOI: 10.1245/s10434-015-4948-7]

53 **Sood A**, Ahuja V, Kedia S, Midha V, Mahajan R, Mehta V, Sudhakar R, Singh A, Kumar A, Puri AS, Tantry BV, Thapa BR, Goswami B, Behera BN, Ye BD, Bansal D, Desai D, Pai G, Yattoo GN, Makharia G, Wijewantha HS, Venkataraman J, Shenoy KT, Dwivedi M, Sahu MK, Bajaj M, Abdullah M, Singh N, Singh N, Abraham P, Khosla R, Tandon R, Misra SP, Nijhawan S, Sinha SK, Bopana S, Krishnaswamy S, Joshi S, Singh SP, Bhatia S, Gupta S, Bhatia S, Ghoshal UC. Diet and inflammatory bowel disease: The Asian Working Group guidelines. *Indian J Gastroenterol* 2019; **38**: 220-246 [PMID: 31352652 DOI: 10.1007/s12664-019-00976-1]

54 **Sousa Guerreiro C**, Cravo M, Costa AR, Miranda A, Tavares L, Moura-Santos P, MarquesVidal P, Nobre Leitão C. A comprehensive approach to evaluate nutritional status in Crohn's patients in the era of biologic therapy: a case-control study. *Am J Gastroenterol* 2007; **102**: 2551-2556 [PMID: 17680845 DOI: 10.1111/j.1572-0241.2007.01439.x]

55 **Singh S**, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 110-121 [PMID: 27899815 DOI: 10.1038/nrgastro.2016.181]

56 **Losurdo G**, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. *World J Gastroenterol* 2020; **26**: 7528-7537 [PMID: 33384552 DOI: 10.3748/wjg.v26.i47.7528]

57 **Harper JW**, Zisman TL. Interaction of obesity and inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 7868-7881 [PMID: 27672284 DOI: 10.3748/wjg.v22.i35.7868]

58 **Blain A**, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. *Clin Nutr* 2002; **21**: 51-57 [PMID: 11884013 DOI: 10.1054/clnu.2001.0503]

59 **Hass DJ**, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn's disease. *Clin Gastroenterol Hepatol* 2006; **4**: 482-488 [PMID: 16616354 DOI: 10.1016/j.cgh.2005.12.015]

60 **Pringle PL**, Stewart KO, Peloquin JM, Sturgeon HC, Nguyen D, Sauk J, Garber JJ, Yajnik V, Ananthakrishnan AN, Chan AT, Xavier RJ, Khalili H. Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. *Inflamm Bowel Dis* 2015; **21**: 2304-2310 [PMID: 26181430 DOI: 10.1097/MIB.0000000000000498]

61 **Nic Suibhne T**, Raftery TC, McMahon O, Walsh C, O'Morain C, O'Sullivan M. High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. *J Crohns Colitis* 2013; **7**: e241-e248 [PMID: 23040290 DOI: 10.1016/j.crohns.2012.09.009]

62 **Flores A**, Burstein E, Cipher DJ, Feagins LA. Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. *Dig Dis Sci* 2015; **60**: 2436-2445 [PMID: 25799938 DOI: 10.1007/s10620-015-3629-5]

63 **Seminerio JL**, Koutroubakis IE, Ramos-Rivers C, Hashash JG, Dudekula A, Regueiro M, Baidoo L, Barrie A, Swoger J, Schwartz M, Weyant K, Dunn MA, Binion DG. Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; **21**: 2857-2863 [PMID: 26241001 DOI: 10.1097/MIB.0000000000000560]

64 **McKenna NP**, Habermann EB, Zielinski MD, Lightner AL, Mathis KL. Body mass index: Implications on disease severity and postoperative complications in patients with Crohn's disease undergoing abdominal surgery. *Surgery* 2019; **166**: 703-708 [PMID: 31262567 DOI: 10.1016/j.surg.2019.04.038]

65 **Hicks G**, Abdulaal A, Slesser AAP, Mohsen Y. Outcomes of inflammatory bowel disease surgery in obese *vs* non-obese patients: a meta-analysis. *Tech Coloproctol* 2019; **23**: 947-955 [PMID: 31531732 DOI: 10.1007/s10151-019-02080-0]

66 **Wick EC**, Hirose K, Shore AD, Clark JM, Gearhart SL, Efron J, Makary MA. Surgical site infections and cost in obese patients undergoing colorectal surgery. *Arch Surg* 2011; **146**: 1068-1072 [PMID: 21576597 DOI: 10.1001/archsurg.2011.117]

67 **Nakagawa H**, Tanaka K, Sasai H, Nishizawa Y. Providing Weight Loss Support to Patients Who Are Obese in Preparation for Colorectal Cancer Surgery to Reduce Surgical Site Infection Risk: A Mixed-methods Study. *Wound Manag Prev* 2020; **66**: 23-32 [PMID: 32614328]

68 **Wolfe BM**, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. *Circ Res* 2016; **118**: 1844-1855 [PMID: 27230645 DOI: 10.1161/CIRCRESAHA.116.307591]

69 **Aziz M**, Haghbin H, Sharma S, Fatima R, Ishtiaq R, Chandan S, Mohan BP, Lee-Smith W, Hassan M, Nawras A. Safety of bariatric surgery in patients with inflammatory bowel disease: A systematic review and meta-analysis. *Clin Obes* 2020; **10**: e12405 [PMID: 32877572 DOI: 10.1111/cob.12405]

70 **Garg R**, Mohan BP, Ponnada S, Singh A, Aminian A, Regueiro M, Click B. Safety and Efficacy of Bariatric Surgery in Inflammatory Bowel Disease Patients: a Systematic Review and Meta-analysis. *Obes Surg* 2020; **30**: 3872-3883 [PMID: 32578179 DOI: 10.1007/s11695-020-04729-4]

71 **Mohapatra S**, Gangadharan K, Pitchumoni CS. Malnutrition in obesity before and after bariatric surgery. *Dis Mon* 2020; **66**: 100866 [PMID: 31301800 DOI: 10.1016/j.disamonth.2019.06.008]

72 **Barazzoni R**, Gortan Cappellari G. Double burden of malnutrition in persons with obesity. *Rev Endocr Metab Disord* 2020; **21**: 307-313 [PMID: 32766943 DOI: 10.1007/s11154-020-09578-1]

73 **Li Y**, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Cao L, Shen B, Li N, Li J. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn's disease. *Colorectal Dis* 2015; **17**: 225-234 [PMID: 25307174 DOI: 10.1111/codi.12798]

74 **Stidham RW**, Waljee AK, Day NM, Bergmans CL, Zahn KM, Higgins PD, Wang SC, Su GL. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn's disease. *Inflamm Bowel Dis* 2015; **21**: 1306-1313 [PMID: 25822011 DOI: 10.1097/MIB.0000000000000360]

75 **Wei Y**, Zhu F, Gong J, Yang J, Zhang T, Gu L, Zhu W, Guo Z, Li Y, Li N, Li J. High Visceral to Subcutaneous Fat Ratio Is Associated with Increased Postoperative Inflammatory Response after Colorectal Resection in Inflammatory Bowel Disease. *Gastroenterol Res Pract* 2018; **2018**: 6270514 [PMID: 29849595 DOI: 10.1155/2018/6270514]

76 **Ünal NG**, Oruç N, Tomey O, Ömer Özütemiz A. Malnutrition and sarcopenia are prevalent among inflammatory bowel disease patients with clinical remission. *Eur J Gastroenterol Hepatol* 2021 [PMID: 33470696 DOI: 10.1097/MEG.0000000000002044]

77 **Cruz-Jentoft AJ**, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* 2010; **39**: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]

78 **Cruz-Jentoft AJ**, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; **48**: 16-31 [PMID: 30312372 DOI: 10.1093/ageing/afy169]

79 **Erős A**, Soós A, Hegyi P, Szakács Z, Benke M, Szűcs Á, Hartmann P, Erőss B, Sarlós P. Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease: a meta-analysis. *Surg Today* 2020; **50**: 1138-1150 [PMID: 31617016 DOI: 10.1007/s00595-019-01893-8]

80 **Galata C**, Hodapp J, Weiß C, Karampinis I, Vassilev G, Reißfelder C, Otto M. Skeletal Muscle Mass Index Predicts Postoperative Complications in Intestinal Surgery for Crohn's Disease. *JPEN J Parenter Enteral Nutr* 2020; **44**: 714-721 [PMID: 31444789 DOI: 10.1002/jpen.1696]

81 **Adams DW**, Gurwara S, Silver HJ, Horst SN, Beaulieu DB, Schwartz DA, Seidner DL. Sarcopenia Is Common in Overweight Patients with Inflammatory Bowel Disease and May Predict Need for Surgery. *Inflamm Bowel Dis* 2017; **23**: 1182-1186 [PMID: 28410342 DOI: 10.1097/MIB.0000000000001128]

82 **Aleixo GFP**, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2020; **145**: 102839 [PMID: 31877534 DOI: 10.1016/j.critrevonc.2019.102839]

83 **Lee CM**, Kang J. Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 2020; **11**: 1270-1282 [PMID: 32483936 DOI: 10.1002/jcsm.12575]

84 **Miljkovic I**, Zmuda JM. Epidemiology of myosteatosis. *Curr Opin Clin Nutr Metab Care* 2010; **13**: 260-264 [PMID: 20179586 DOI: 10.1097/MCO.0b013e328337d826]

85 **O'Brien S**, Kavanagh RG, Carey BW, Maher MM, O'Connor OJ, Andrews EJ. The impact of sarcopenia and myosteatosis on postoperative outcomes in patients with inflammatory bowel disease. *Eur Radiol Exp* 2018; **2**: 37 [PMID: 30460523 DOI: 10.1186/s41747-018-0072-3]

86 **Kuppinger D**, Hartl WH, Bertok M, Hoffmann JM, Cederbaum J, Küchenhoff H, Jauch KW, Rittler P. Nutritional screening for risk prediction in patients scheduled for abdominal operations. *Br J Surg* 2012; **99**: 728-737 [PMID: 22362084 DOI: 10.1002/bjs.8710]

87 **Brennan GT**, Ha I, Hogan C, Nguyen E, Jamal MM, Bechtold ML, Nguyen DL. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis. *Eur J Gastroenterol Hepatol* 2018; **30**: 997-1002 [PMID: 29738326 DOI: 10.1097/MEG.0000000000001162]

**Footnotes**

**Conflict-of-interest statement:** Santana GO has served on advisory boards for Janssen, as a speaker for Abbvie, Ferring, Janssen, Takeda, and UCB Pharma, and has conducted research for Janssen, Lilly, Pfizer, Roche, and Takeda. The other authors declare that they have no conflicting interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 22, 2021

**First decision:** May 8, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Lyutakov I, Wu Z **S-Editor:** Fan JR **L-Editor: P-Editor:**